Effect of the long-acting, inhaled β2-agonist formoterol on the quality of sleep in healthy subjects

Somnologie

Volumn 3, Issue 5, 1999, Pages 260-263

  Konermann, M ^a,c   Brand, Sabine ^a   Rawert, B ^a   Sanner, B M ^b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c Marienkrankenhaus   (Germany)

Author keywords

2 gonists; Nocturnal asthma; Polysomnography; Sleep

Indexed keywords

FORMOTEROL; THEOPHYLLINE;

ADULT; AROUSAL; ARTICLE; ASTHMA; DRUG ACTIVITY; FEMALE; HUMAN; MALE; NORMAL HUMAN; POLYSOMNOGRAPHY; RESPIRATORY DISTRESS; SLEEP; SLEEP STAGE;

EID: 0032733539     PISSN: 14329123     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11818-999-0033-4     Document Type: Article

References (27)

1. American Thoracic Society. Indications and standards for cardiopulmonary sleep studies. Am Rev Resp Dis 139:559-568, 1989.
2. Barnes N: Nocturnal asthma: control and management options. Prescriber 12:89-94, 1996.
3. Baughman RP, Loudon RG: The utility of a long-acting sympathicomimetic agent, procaterol, for nocturnal asthma. Chest 93:285-288, 1988.
4. Bush RK: Nocturnal asthma: mechanisms and the role of theophylline in treatment. Postgrad Med J 67 (suppl) 4:20-24, 1991.
5. Douglas NJ: Treatment of nocturnal asthma. Monaldi Arch Chest Dis 48:262-264, 1993.
6. 2-agonist formoterol Turbohaler® dangerous? Eur Respir J 10, suppl 25:103, 1997.
7. Faurschou P, Engel AM, Haanaes OC: Salmeterol in two different doses in the treatment of nocturnal bronchial asthma poorly controlled by other therapies. Allergy 49: 827-832, 1994.
8. 2 agonist. Br Med J 301:1365-1368, 1990.
9. Fitzpatrick MF, Engleman H, Whyte KF, Deary IJ, Shapiro CM, Douglas NJ: Morbidity in nocturnal asthma: sleep quality and daytime cognitive performance. Thorax 46:569-573, 1991.
10. Kardos P, Friedrich P: Comparison between four weeks' treatment with formoterol versus fenoterol in patients with reversible obstructive respiratory tract diseases. In: Sybrecht G (ed): Formoterol - a new long-acting bronchodilator. Hans Huber Publishers, Toronto - Lewiston N.Y. - Bern - Stuttgart pp 57-59, 1997.
11. Maesen FPV, Smeets JJ, Gubbelmans HLL, Zweers PGMA: Formoterol in the treatment of nocturnal asthma. Chest 98:866-870, 1990.
12. Marek W: Chronobiologie des Bronchialsystems. Pneumologie 51:430-439, 1997.
13. Matthys H: Formoterol versus Fenoterol bei nächtlichem Asthma bronchiale. In: Nolte D, Burghele A (Hrsg): Bronchospasmolyse mit Beta-2-Sympathikomimetika. Erfahrungen mit dem langwirksamen Dosier-Aerosol Formoterol. Dustri-Verlag, München, pp 123-130, 1997.
14. Millman RP: Treatment of nocturnal asthma. Allergy Proc 14:9-12, 1993.
15. Muir JF, Bertin L, Georges D: French Multicentre Study Group. Salmeterol versus slow-release theophylline combined with ketotifen in nocturnal asthma: a multicentre trial. Eur Respir 5: 1997-1200, 1992.
16. Pastelak-Price C: Das internationale 10-20-System zur Elektrodenplazierung: Begründung, praktische Anleitung zu den Meßschritten und Hinweise zum Setzen der Elektroden. EEG-Labor 5:49-72, 1983.
17. Pauwels RA, Löfdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A: Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 337:1405-1411, 1997.
18. Probst D, Müller D: Asthma bronchiale und Foradil. Georg Thieme Verlag, Stuttgart, New York, 1997.
19. Rechtschaffen A, Kales A: A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. U.S. Public Health Service. U.S. Governement Printing Office. Washington D.C. 1968.
20. Rhind GB, Connaughton JJ, McFie J, Douglas NJ, Flenley DC: Sustained release choline theophyllinate in nocturnal asthma. Br Med J 291:1605-1607, 1985.
21. 2-Sympathikomimetika. Poster Kongress der Deutschen Gesellschaft für Pneumologie, 6.7.1995.
22. Schnabel D, Sybrecht GW, Hemmerling T: Die protektive Wirksamkeit von Formoterol im Vergleich zu Theophyllin bei Patienten mit nächtlichem Asthma bronchiale. In: Nolte D, Burghele A (Hrsg): Bronchospasmolyse mit Beta-2-Sympathikomimetika. Erfahrungen mit dem langwirksamen Dosier-Aerosol Formoterol. Dustri-Verlag, München, pp 113-122, 1997.
23. Selby C, Engleman HM, Fitzpatrick MF, Sime PM, Mackay TW, Douglas NJ: Inhaled salmeterol or oral theophylline in nocturnal asthma? Am J Respir Crit Care Med 155:104-108, 1997.
24. Turner-Warwick M: Epidemiology of nocturnal asthma. Am J Med 85, suppl. 1B:6-8, 1988.
25. Ukena D, Koper I, Braun H, Leutz M, Schlimmer P, Sybrecht GW: Therapie des nächtlichen Asthmas: Salmeterol versus abendliche Einnahme von retardiertem Theophyllin - Vergleich der Wirksamkeit und der Verträglichkeit. Pneumologie 51: 317-323, 1997.
26. Van Keimpema ARJ, Ariaansz M, Nauta JJP, Postmus PE: Subjective sleep quality and mental fitness in asthmatic patients. J Asthma 32:69-74, 1995.
27. Zwillich CW, Neagley SR, Cicutto L, White DP, Martin RJ: Nocturnal asthma therapy: inhaled bitolterol versus sustained-release theophylline. Am Rev Respir Dis 139:470-474, 1989.